Lecalcif

Colecalciferol, the active ingredient in Lecalcif, is a Vitamin D3 presented as an oral supplement for oral use. It is used to treat vitamin D deficiency, hypocalcemia and to support bone health in adults and children.

GNH USA supplies Lecalcif as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecalcif (colecalciferol) is used in the management of disorders related to vitamin D deficiency and calcium metabolism.

Vitamin D deficiency: restores adequate serum 25‑hydroxyvitamin D levels to support normal bone metabolism. Hypocalcemia: increases calcium absorption to correct low blood calcium concentrations. Bone health support: aids in maintaining bone mineral density and reducing risk of osteomalacia.

Colecalciferol may cause a range of adverse reactions, most of which are mild and dose‑related.

Common Side Effects: - Nausea - Constipation - Headache - Dry mouth - Mild hypercalcemia (asymptomatic)

Serious or Rare Side Effects: - Hypervitaminosis D leading to severe hypercalcemia - Renal stones - Cardiac arrhythmias due to high calcium - Severe allergic reactions (anaphylaxis) - Hyperphosphatemia

When using Lecalcif, consider the following precautions to ensure safe and effective therapy.

Assess baseline serum calcium and 25‑hydroxyvitamin D levels: determine need for supplementation. Monitor for signs of hypercalcemia during therapy: especially in patients with renal disease. Use caution in patients with sarcoidosis or granulomatous diseases: they may have increased conversion to active vitamin D. Avoid concurrent high‑dose calcium or vitamin A supplements without medical supervision. Pregnancy and lactation: use only if clearly needed and prescribed by a healthcare professional. Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Colecalciferol can interact with several medicines, altering calcium balance or vitamin D metabolism.

Major Interactions (Avoid): - Thiazide diuretics: increase risk of hypercalcemia. - High‑dose calcium supplements: additive effect on calcium levels. - Vitamin A excess: potentiates hypercalcemia.

Moderate Interactions (Monitor Closely): - Glucocorticoids: reduce vitamin D effectiveness, may require dose adjustment. - Anticonvulsants (e.g., phenytoin, phenobarbital): increase vitamin D catabolism. - Bariatric surgery patients: altered absorption may affect efficacy. - Bisphosphonates: concurrent use may affect calcium homeostasis.